The abstract is read at the publisher; the summary is JClub's.
CCNE1 amplification occurs in 4.0% of 6,318 breast cancers and is linked to shorter first-line THP PFS in HER2+ disease, with 8.4 vs 18.0 months.
- Why it matters: The clinical and genomic significance of CCNE1 amplification in breast cancer is unclear, limiting its use as a biomarker or therapeutic target.
- What they did: Using MSK Breast Translational database patients with targeted sequencing (Jan 2014–Oct 2025), the study quantified allele-specific copy number with FACETS and compared clinicogenomic features and PFS by receptor subtype.
- The result: CCNE1-amplified tumors show aggressive pathology and genomic instability (including TP53 alterations, high fraction of genome altered, and whole genome doubling), and predict poorer HER2+ outcomes on first-line THP.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.